Skip to main content
SpringerLink
Log in

TRANSPLANTATION

Cell therapy can enable minimization of immunosuppression

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Long-term immunosuppression in transplant recipients is associated with important adverse effects including increased risk of infection and malignancy. New data from the ONE Study suggests that use of cell-based medicinal products containing regulatory immune cells is a potentially useful therapeutic strategy to enable minimization of immunosuppression in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sawitzki, B. et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet 395, 1627–1639 (2020).

    Article  CAS  Google Scholar 

  2. Sasaki, H. et al. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Hum. Immunol. 79, 258–265 (2018).

    Article  Google Scholar 

  3. Sykes, M. Immune monitoring of transplant patients in transient mixed chimerism tolerance trials. Hum. Immunol. 79, 334–342 (2018).

    Article  Google Scholar 

  4. Scandling, J. D. et al. Macrochimerism and clinical transplant tolerance. Hum. Immunol. 79, 266–271 (2018).

    Article  CAS  Google Scholar 

  5. Leventhal, J. R. et al. Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells. Hum. Immunol. 79, 277–282 (2018).

    Article  CAS  Google Scholar 

  6. Leventhal, J. R. & Ildstad, S. T. Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: the importance of durable chimerism. Hum. Immunol. 79, 272–276 (2018).

    Article  Google Scholar 

  7. Leventhal, J. R. & Mathew, J. M. Outstanding questions in transplantation: tolerance. Am. J. Transplant. 20, 348–354 (2020).

    Article  Google Scholar 

  8. Levitsky, J. et al. Immunosuppression withdrawal in liver transplant recipients on sirolimus. Hepatology https://doi.org/10.1002/hep.31036 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    James M. Mathew & Joseph R. Leventhal

  2. Department of Microbiology–Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    James M. Mathew

Authors
  1. James M. Mathew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph R. Leventhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to James M. Mathew or Joseph R. Leventhal.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathew, J.M., Leventhal, J.R. Cell therapy can enable minimization of immunosuppression. Nat Rev Nephrol 16, 486–487 (2020). https://doi.org/10.1038/s41581-020-0330-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-020-0330-5

  • Springer Nature Limited

Search

Navigation